- Investigator, Urologic Oncology Branch
Dr. Agarwal is a tenure-track investigator and the Head of the Bladder Cancer Section in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, MD. He received his M.D. from the Cornell (Weill) University School of Medicine in New York, New York. He then completed his urology residency at Case Western Reserve University in Cleveland, Ohio. He then went on to the University of Texas MD Anderson Cancer Center where he completed a fellowship in urologic oncology. Before coming to the NIH, Dr. Agarwal was a faculty member at the Henry Ford Hospital Vattikuti Urology Institute where he served as the Director of Robotic Bladder Surgery. Dr. Agarwal is a Board Certified and fellowship trained Urologic Oncologic Surgeon. Dr. Agarwal specializes in multidisciplinary management of bladder cancer and complex surgical techniques including robotic cystectomy and continent urinary diversions. He is also an expert in other urologic cancers including prostate, testicular, and penile carcinoma. His clinical and laboratory research focus on all aspects of bladder cancer, specifically, BCG-refractory disease and molecular targeted therapy.
- (2019). ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. WORLD JOURNAL OF UROLOGY. 37(1), 51-60.
- (2019). Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. JOURNAL OF IMMUNOLOGY. 202(12), 3458-3467.
- (2019). Proteasome inhibition disrupts the metabolism of fumarate hydratase-deficient tumors by downregulating p62 and c-Myc. Scientific Reports. 9,
- (2018). Bilateral Ureteroenteric Strictures: A Case of the "Reverse 7". UROLOGY. 118, E3-E4.